Latest News Releases Keyword Search Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 8/12/26 Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia 8/7/26 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist 7/30/26 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results 7/23/26 Neurocrine Biosciences Announces Key Leadership Hiring, Promotions 7/21/26 Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer 7/9/26 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results Resources Email Alerts 2025 Annual Report 2026 Proxy Statement Webcasts & Presentations
8/12/26 Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
8/7/26 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
7/9/26 Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results